Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
October 09 2013 - 3:11PM
Marketwired
Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen
BioPharma Dividend to Be Paid to Shareholders
Dividend Is Approximately 40% Payout of Regen's Issued and
Outstanding Shares
SAN DIEGO, CA--(Marketwired - Oct 9, 2013) - Bio-Matrix
Scientific Group, Inc. (OTCQB: BMSN) today announced that its Board
of Directors has authorized a distribution on a pro rata basis as a
dividend in kind of 20,000,000 of the common shares of Regen
BioPharma Inc. ("Dividend Shares"), a subsidiary of
BMSN, to:
(a) Holders of record of the outstanding common shares of BMSN
as of the record date
(b) Holders of record of the shares of any outstanding series of
the preferred shares of BMSN as of the record date.
Bio-Matrix' Chairman & CEO David Koos stated, "The record
date is anticipated to be set as soon as possible after the Form
S-1 registering the Dividend Shares under the Securities Act of
1933 is declared effective by the United States Securities and
Exchange Commission (SEC). On a pro rata basis, both common
and all classes of preferred shareholders will receive this
dividend. The Company expects the registration statement to be
filed within the next few days with the SEC."
There are 51,610,000 currently outstanding in Regen BioPharma
Inc., with Bio-Matrix Scientific Group Inc. owning 50,010,000 of
these common shares.
About Regen BioPharma: Regen BioPharma, Inc., a
subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a
biotechnology company focused on identifying undervalued
regenerative medicine applications in the stem cell space and
rapidly advancing these technologies through pre-clinical and Phase
I/ II clinical trials. For more information refer to the company's
website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking
statements. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to
which forward looking statements are subject include, but are not
limited to, the effect of government regulation, competition and
other material risks.
Contact: Bio-Matrix Scientific Group, Inc. and Regen BioPharma
Inc. David R. Koos, PhD Chairman & Chief Executive Officer
619-702-1404 www.regenbiopharma.com